The use of almost every antibiotic increases the chances of Clostridioides difficile infection, and that includes the drugs that are used to treat C diff, a study states.
When it comes to what circumstances help breed Clostridioides difficile infection (CDI), there are some that could be called the usual suspects. They include increased age, hospitalization, use of proton pump inhibitors, and use of antibiotics, according to a recent study out of Pakistan. That study, published in Cureus,1 looked at data from 200 patients diagnosed with
C difficile–associated diarrhea (CDAD) at a tertiary care hospital in Pakistan between June 2020 and March 2021, along with 200 patients without CDAD in a control group.
“Identifying and addressing the risk factors associated with CDI will help [reduce] the incidence of infection and associated complications,” the authors, led by Aarzoo Gupta of Vardhman Mahavir Medical College and Safdarjung Hospital in Faridabad, India, wrote.
The study included detailed histories of patients’ use of treatments (antibiotics, proton pump inhibitors, and histamine 2 receptor antagonists), previous CDI diagnoses, and hospitalization in the past 30 days. Investigators also noted patients’ body mass index (BMI) and comorbidities including diabetes, chronic kidney disease (CKD), hypertension, and malignancy.
In the case group, 31 patients were older than 65 (15.5%), compared with 16 (8%) in the control group (OR [odds ratio], 2.10 [1.11-3.99]; P = .02). “This age group is not only termed as a risk factor for CDI but such patients also demonstrate poor prognosis, leading to increased clinical severity and death rates,” the authors wrote.
Patients with CDI also had significantly higher hospitalization (25.5% vs 6%; OR, 5.36 [2.75-10.42]; P < .0001), use of proton pump inhibitors in past 30 days (23.0% vs 10.5%; OR, 2.54 [1.45-4.45]; P = .001), and use of antibiotics in the past 30 days (36.0% vs 10.5%; OR, 4.76 [2.80-8.19]; P < .0001).
“Studies have suggested that almost every antibiotic results in an increased chance of developing CDI,” the authors wrote. “This also includes the drugs that are used to treat CDI, namely metronidazole and vancomycin.”
Other risk factors included a BMI above 25 kg/m2 (31% vs 21%; OR, 1.69 [1.07-2.65]; P = .02), diabetes (27% vs 16%; OR, 1.94 [1.18-2.17]; P = .008), CKD (19% vs 9.5%; OR, 2.23 [1.23-4.03]; P = .007), and malignancy (6% vs 2%; OR, 3.12 [0.99-9.86]; P = .05).
“Given the findings [above], our study suggests that the use of acid-suppressive agents should be carefully considered, and the over-the-counter availability of these agents should be discouraged,” the authors wrote. “This would help the doctors to keep a check in order to avoid overdose. Moreover, hygiene practices, such as hand washing practices, sterilizing used [equipment] at the hospital, using clean medical devices, etc, should be adopted to avoid infection risk. Maximum management of antibiotic intake should also be taken into consideration.”
CDI is the leading cause of health care–associated infections, causing about a half million infections and $1 billion in health care costs each year. Although CDI is often associated with health care settings, a recent study by investigators at the University of Houston found that the bacterium is prevalent in a variety of settings, including on 45% of shoe soles.2 Healthy people can carry CDI without illness or symptoms.
This article originally appeared in Contagion®3
References:
Herpes and Dentistry: A Silent But Serious Concern
February 21st 2025Herpes infections pose significant risks in dentistry. JoAnn Gurenlian, RDH, PhD, presented prevention, treatment, occupational hazards, and a potential breakthrough in gene therapy that could revolutionize herpes management at the Midwinter Meeting.
Chicago Dental Society Honors Drs Joseph Hagenbruch and Mark Lingen for Excellence in Dentistry
February 21st 2025The Chicago Dental Society honored Dr. Joseph Hagenbruch and Dr. Mark Lingen for their leadership, research, and dedication to advancing dentistry and improving oral health care access.
From Sterilization Tech to Infection Control Advocate: Sherrie Busby’s Inspiring Dental Journey
February 20th 2025Sherrie Busby, EDDA, CDSO, CDIPC, shares her journey from dental assisting to infection control advocacy, highlighting her passion for education, her role at Heartland Dental, and her exciting transition to a new chapter.
Innovation and Infection Control: Highlights From W&H at Chicago Dental Midwinter Society Meeting
February 19th 2025Doris Schneider, senior marketing manager for North America for W&H North America, shares insights into the 160th Chicago Dental Society Midwinter Meeting, showcasing the Lexa Mini rapid sterilizer and Sanaa Power handpiece, designed for efficient sterilization and effortless dental procedures.